Predictive Value of Tumor Mutation Burden for PD-1/PD-L1 Inhibitors Treatment on Non-small Cell Lung Cancer: A Meta-analysis

Predictive Value of Tumor Mutation Burden for PD-1/PD-L1 Inhibitors Treatment on Non-small Cell Lung Cancer: A Meta-analysis

Objective To investigate the relation between TMB and the efficiency of PD-1/PD-L1 inhibitors treatment for non-small-cell lung cancer. Methods Studies were searched from PubMed, Embase, Cochrane Library database, Chinese Biomedical Literature Database and Wanfang Database up to March 25, 2020. RevM...

Full description

Bibliographic Details
Main Authors:	SHEN Shijun, WANG Qiaoli, YANG Jinjiang, LI Guojian, LI Mengli, ZHANG Xiaoli, GAN Ping
Format:	Article
Language:	zho
Published:	Magazine House of Cancer Research on Prevention and Treatment 2021-03-01
Series:	Zhongliu Fangzhi Yanjiu
Subjects:	mmunotherapy meta-analysis non-small cell lung cancer pd-1/pd-l1 inhibitors tumor mutation burden
Online Access:	http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.0765.htm

Similar Items

Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis
by: Jiaxin Zhu, et al.
Published: (2019-06-01)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
by: Ming Yi, et al.
Published: (2018-08-01)

The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis
by: He Ba, et al.
Published: (2021-11-01)

Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors
by: GAN Zi-ying, TANG Hui
Published: (2022-04-01)

Advances in the Influence of EGFR Mutation on the PD-L1 Expression in Non-small Cell Lung Cancer
by: Xiaoyu ZHI, et al.
Published: (2019-12-01)

Does it fit in your pocket? economic burden of PD-1 inhibitors' toxicity in the supplementary health system: evidence from Brazil
by: Hugo Santos Duarte, et al.
Published: (2023-07-01)

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
by: Ruiting Li, et al.
Published: (2021-06-01)

The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers
by: Omid Kooshkaki, et al.
Published: (2020-07-01)

Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
by: Yixi Zhang, et al.
Published: (2021-11-01)

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
by: YU Lin, et al.
Published: (2021-08-01)

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy
by: Hongbo Zhang, et al.
Published: (2021-06-01)

Risk of immune‐related pneumonitis for PD1/PD‐L1 inhibitors: Systematic review and network meta‐analysis
by: Yafang Huang, et al.
Published: (2019-05-01)

Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review
by: Yiru Zhang, et al.
Published: (2023-01-01)

Incidence and Risk of PD-1/PD-L1 Inhibitor-associated Pneumonia in Advance Cancer Patients: A Meta-analysis
by: Kang CHEN, et al.
Published: (2020-11-01)

The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis
by: Yuan Tian, et al.
Published: (2021-07-01)

Comparative Impact of PD-1 and PD-L1 Inhibitors on Advanced Esophageal or Gastric/Gastroesophageal Junction Cancer Treatment: A Systematic Review and Meta-Analysis
by: SuA Oh, et al.
Published: (2021-08-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
by: Tianrui Yang, et al.
Published: (2021-02-01)

The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy
by: Lu Wen, et al.
Published: (2021-12-01)

PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas
by: Zhichao Tian, et al.
Published: (2022-08-01)

Beyond PD-L1 Markers for Lung Cancer Immunotherapy
by: Kamila Wojas-Krawczyk, et al.
Published: (2019-04-01)

Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis
by: Jue Zhu, et al.
Published: (2021-08-01)

Liver metastases and the efficacy of the PD-1 or PD-L1 inhibitors in cancer: a meta-analysis of randomized controlled trials
by: Shan Li, et al.
Published: (2020-01-01)

A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma
by: Congkuan Song, et al.
Published: (2021-01-01)

Immune-related cardiovascular toxicities of PD-1/PD-L1 inhibitors in solid tumors: an updated systematic review and meta-analysis
by: Chi Zhang, et al.
Published: (2024-01-01)

Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis
by: Long Ma, et al.
Published: (2021-08-01)

High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma
by: Xi Chen, et al.
Published: (2022-01-01)

Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction
by: Fengling Wang, et al.
Published: (2023-02-01)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021-09-01)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
by: Yuanyuan Wang, et al.
Published: (2021-05-01)

Key differences between anti-PD-1/PD-L1 inhibitors
by: N. V. Zhukova, et al.
Published: (2022-06-01)

Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (Neo) Adjuvant Therapy for Malignant Melanoma
by: ZOU Hanhui, et al.
Published: (2020-02-01)

PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism
by: Hao Dong, et al.
Published: (2022-04-01)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
by: Qian Li, et al.
Published: (2022-12-01)

Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers
by: Shun-Long Ou, et al.
Published: (2023-04-01)

PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma
by: Yu-Min Zhong, et al.
Published: (2022-10-01)

Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
by: Runsen Jin, et al.
Published: (2020-08-01)

Efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis
by: Siyuan Zeng, et al.
Published: (2023-03-01)

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
by: Qing Tang, et al.
Published: (2022-09-01)

Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
by: Shuang Huang, et al.
Published: (2023-11-01)

Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era
by: SHAN Baoen
Published: (2023-09-01)